← Back to Clinical Trials
Recruiting NCT06673953

NCT06673953 Effect of Respiratory Trainer on Cardiopulmonary Functions in Patients with Upper Cross Syndrome Post-Cardiac Surgery

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06673953
Status Recruiting
Phase
Sponsor Cairo University
Condition Post Coronary Artery Bypass Grafting
Study Type INTERVENTIONAL
Enrollment 60 participants
Start Date 2024-08-28
Primary Completion 2025-01-20

Trial Parameters

Condition Post Coronary Artery Bypass Grafting
Sponsor Cairo University
Study Type INTERVENTIONAL
Phase N/A
Enrollment 60
Sex MALE
Min Age 45 Years
Max Age 55 Years
Start Date 2024-08-28
Completion 2025-01-20
Interventions
Respiratory Muscle Training by (The Breather)Traditional physical therapy program

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

The purpose of this study is to investigate if there is any effect of the respiratory training on cardiopulmonary functions in patients with upper cross syndrome post-cardiac surgery. Hypothesis: Null hypothesis: There is no effect of the respiratory training on pulmonary functions in patients with upper cross syndrome post-cardiac surgery.

Eligibility Criteria

Inclusion Criteria: * Sixty post-CABG-male-patients for at least three months and their age ranges from 45 to 55 years old. * Craniovertebral angle \< 51°, but not less than 30°. * Non-specific chronic neck pain: defined as neck pain without an identifiable pathological cause and attributed to poor posture without radiation to upper limbs. * VAS score between 3-7. * Their body mass index ranges from (25 -29.9) kg/m2. * Values of FEV1 and FVC lower than 80% Exclusion Criteria: * Rheumatoid arthritis, cervical disc pathology, and traumatic neck pain. * History of respiratory disease and clinical signs of severe cardiac events. * Neurological disorders which affect the diaphragm. * Patients whose BMI is less than 25, or greater than 30 kg/m2. * Smokers. * Values of FEV1 and FVC higher than 80% * Patients with chronic obstructive pulmonary disease or asthma.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology